May 16, 2013
/PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that CEO and President,
, will present at the Annual World Stem Cells and Regenerative Medicine Congress on
Thursday, May 23
. Mr. Garr's talk, "Understanding the Practicalities of Using Innovative Therapies on Patients," at
, will explore how cell therapies will be used by clinicians and integrated into hospital settings (
). Mr. Garr will also give an update on Neuralstem's clinical programs in both the cell therapy and small molecule platforms, and is expected to comment on the presentation Dr.
will make on
at the Romanian Neurological Society Congress held in
, in which she will present data from Neuralstem's Phase I ALS trial. The Stem Cell Congress presentation will be webcast and viewable at
Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem completed an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as
's disease, in
, and has received FDA approval to begin Phase II. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy.
In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic stroke and glioblastoma (brain cancer). The company received approval to commence a Phase I safety trial in chronic spinal cord injury in
Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions. The company is in the last cohort of a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include traumatic brain injury (TBI), Alzheimer's disease, and post-traumatic stress disorder (PTSD).